Gano Kyle's Form 4 filing
Neurocrine Biosciences Inc (NBIX) · filed Feb 12, 2025
- Accession no.
- 0000914475-25-000049
- Filed
- Feb 12, 2025
- Trade date
- Feb 8-10, 2025
- Filing delay
- 4 daysLate
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $116.0K. It was filed 4 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gano KyleCIK 0001567160 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 8, 2025 | Common Stock | MOption exerciseAcquired | +1,860 | $0.00 | $0 | 138,638 | Direct | |
| Feb 10, 2025 | Common Stock | SSaleDisposed | −980 | $118.39 | −$116,022.2 | 137,658 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 8, 2025 | Common Stock | MOption exerciseDisposed | −1,860 | $0.00 | $0 | 0 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.